Search

Introduction. Antiphospholipid Antibodies (aPL) has been associated with thrombotic events. The objective of this study was to investigate the prevalence of aPL in a group of Chilean patients with venous and arterial thrombosis. Patients and Methods. Two hundred twenty six patients with venous and arterial thrombosis and 95 healthy controls were included in this study. Anticardiolipin (aCL), Anti-β2Glycoprotein I (anti-β2GPI) and Antiprothrombin (aPT) antibodies, were determined by ELISA using "in-house" assays. Results. Eighty eight out of 226 (38.9%) patients with thrombosis had some type of aPL. The prevalence of aCL, anti-β2GPI and aPT in patients with TV y TA, and in control group, shows in the following table: Twelve patients (5.3%) were positive for mixture of aPL. IgG, IgM and IgA isotypes were observed in aCL, Anti-β2GPI and aPT antibodies. Twenty four out of 78 (30.8%) patients with deep venous thrombosis, 2/14 (14.3%) with retinal venous thrombosis 17/68 (25.0%) with ischemic stroke and 14/66 (21.2%) with acute myocardial infarction, were positive for aCL antibodies. Anti-β2GPI and aPT antibodies were also present in these groups although in minor proportion. Conclusion. Our results show an important prevalence of aPL in patients with thrombosis, and aCL and aPT seem to be a risk factor of venous and arterial thrombosis. [ABSTRACT FROM AUTHOR]

Background: Factor V Leiden and G20210A mutation of prothrombin gene are two important genetic polymorphisms associated with an increased risk for thrombosis., Aim: To establish the prevalence of factor V Leiden and prothrombin G20210A mutation in the Chilean population and their association to venous and arterial thromboembolism., Material and Methods: A case-control study was conducted where 149 patients with thrombosis (87 with arterial and 62 with venous thrombosis) confirmed by CAT-scan, electrocardiogram and cardiac enzymes or Doppler depending on the case, and 160 healthy blood donors were genetically analyzed for the presence of both polymorphisms., Results: Factor V Leiden mutation was found in 5.4% of patients and in 1.3% of healthy controls (p=0.04). Heterozygosity for G20210A prothrombin mutation was found in 5.4% of patients and in 2.5% of the control group (p=NS). When arterial and venous thrombosis were considered as separate entities, 4.6% of patients with arterial thrombosis and 6.5% with venous thrombosis presented factor V Leiden (p=NS). Likewise, 8.1% of patients with venous thrombosis and 3.5% of patients with arterial thrombosis had G20210A prothrombin mutation (p=NS)., Conclusions: In non selected consecutive Chilean patients with arterial and venous thrombosis the frequency of factor V Leiden and prothrombin G20210A is less than we could expect from their prevalence in the general population.